作者
Arnab Datta, Chris J Scotton, Rachel C Chambers
发表日期
2011/5
来源
British journal of pharmacology
卷号
163
期号
1
页码范围
141-172
出版商
Blackwell Publishing Ltd
简介
Pulmonary fibrosis represents the end stage of a number of heterogeneous conditions and is, to a greater or lesser degree, the hallmark of the interstitial lung diseases. It is characterized by the excessive deposition of extracellular matrix proteins within the pulmonary interstitium leading to the obliteration of functional alveolar units and in many cases, respiratory failure. While a small number of interstitial lung diseases have known aetiologies, most are idiopathic in nature, and of these, idiopathic pulmonary fibrosis is the most common and carries with it an appalling prognosis – median survival from the time of diagnosis is less than 3 years. This reflects the lack of any effective therapy to modify the course of the disease, which in turn is indicative of our incomplete understanding of the pathogenesis of this condition. Current prevailing hypotheses focus on dysregulated epithelial–mesenchymal interactions promoting …
引用总数
2011201220132014201520162017201820192020202120222023202471929183415242117212122197
学术搜索中的文章
A Datta, CJ Scotton, RC Chambers - British journal of pharmacology, 2011